-
ASCO GI 2025 | Dr. Jin Li: A New Era for Chemotherapy as the First Oral Paclitaxel Demonstrates Non-Inferiority to Intravenous Administration
The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI) took place from January 23 to 25 in San Francisco, bringing together the latest advancements in digestive tract oncology. Paclitaxel remains one of the most important chemotherapeutic agents for gastric cancer treatment. However, the traditional intravenous (IV) formulation has long been associated with significant adverse effects. Chinese…
-
SABCS 2024 | Professor Matteo Lambertini: Optimizing Treatment Strategies for BRCA-Mutated Breast Cancer and Highlights of the SABCS Conference
In the field of breast cancer, the treatment of patients with BRCA gene mutations has always been a research hotspot. Recently, at the SABCS conference, Professor Matteo Lambertini from the San Martino Hospital of the University of Genoa, Italy, shared the latest findings on the treatment of BRCA-mutated breast cancer in depth (abstract number: GS1-08).…
-
ASCO GU 2025 | Professor Toni Choueiri on the Future of Casdatifan in Clear Cell Renal Cell Carcinoma
The VHL-HIF pathway is one of the most commonly activated pathways in clear cell renal cell carcinoma (ccRCC). Loss of von Hippel-Lindau (VHL) gene function leads to the stabilization of hypoxia-inducible factors HIF-1α and HIF-2α, driving tumor growth and progression. The development of HIF-2α inhibitors, including belzutifan and casdatifan, has introduced new therapeutic strategies for…
-
Findings on Hepatic-like Erythropoietin and Its Role in Erythrocytosis
A recent study published in Blood (November 2024) has identified Hepatic-like Erythropoietin Polycythemia (HEP) as a novel cause of hereditary and acquired erythrocytosis. Researchers discovered mutations in the EPO gene,…
-
Findings on Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma
A recent study published in Blood (November 2024) presents results from the Phase 3 inMIND trial, evaluating the addition of tafasitamab to lenalidomide and rituximab in patients with relapsed or…
-
SOHO 2024 | Dr. Jorge E. Cortes Interprets the ASC4FIRST Study, Aiding in the Optimization of First-line Treatment Options for Newly Diagnosed CML
The advent of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of chronic myeloid leukemia (CML), transforming its management into a chronic disease model and bringing patient life expectancy close to that of the general population. However, some patients experience treatment failure due to intolerance or insufficient response to at least two existing therapies, or…
-
SOHO 2024 | Dr. Grzegorz S. Nowakowski Discusses the Latest Advances in First-line Treatment of DLBCL
Diffuse large B-cell lymphoma (DLBCL), as the most common subtype of non-Hodgkin lymphoma, is highly heterogeneous and poses challenges in treatment. Patient prognosis is influenced by various factors, and while the standard R-CHOP regimen is widely used, its efficacy is limited for high-risk groups such as patients with double-hit lymphoma (DHL), necessitating more precise treatment…
-
Dr. Lugui Qiu: Progress Flourishes with a Precision-Based Lymphoma Diagnosis and Treatment System
Lymphoma is a common malignant disease of the lymphatic system that poses a significant threat to public health. China faces a rapidly increasing burden of lymphatic tumors. The GBD 2019 study shows that China accounts for 10.8% of the world’s new cases of Hodgkin lymphoma and 9.8% of the deaths, as well as 20.1% of…
Connecting Medical Expertise through Media